By 2024, AI-driven drug discovery had moved from proof-of-concept to clinical reality:
- Insilico Medicine's AI-designed drug entered Phase II clinical trials in 2024 — the first drug entirely designed by AI to reach this stage, targeting idiopathic pulmonary fibrosis
- AlphaFold's protein structure database (200+ million predicted structures) has become the most-used resource in structural biology, enabling researchers worldwide to accelerate drug target identification
- DeepMind's GNoME discovered 2.2 million new crystal structures (equivalent to 800 years of human research), with 380,000 predicted to be stable — opening new paths for battery and solar cell development
- AI reduced the average preclinical drug discovery timeline from 4-5 years to under 18 months in multiple programs
Source
Multiple 2024 publications in Nature and Science on AI-driven drug discovery and materials science.